Stability of some atypical antipsychotics in human plasma, haemolysed whole blood, oral fluid, human serum and calf serum

Forensic Science International

Volumn 229, Issue 1-3, 2013, Pages 151-156

  Fisher, Danielle S ^a   Partridge, Suzanne J ^a   Handley, Simon A ^a   Flanagan, Robert J ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Atypical antipsychotics; Haemolysed whole bloods; Instability; Olanzapine; Oral fluid; TDM

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASCORBIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DEHYDROARIPIPRAZOLE; DRUG METABOLITE; EDETIC ACID; HEPARIN; NORCLOZAPINE; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SULPIRIDE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CALF SERUM; CONCENTRATION (PARAMETERS); CONTAINER; CONTROLLED STUDY; DRUG STABILITY; DRUG STORAGE; ENVIRONMENTAL TEMPERATURE; FREEZING; HEMOLYSIS; HUMAN; LIQUID CHROMATOGRAPHY; NONHUMAN; PLASMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; SALIVA; SERUM; TANDEM MASS SPECTROMETRY; THAWING;

EID: 84885949628     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2013.03.021     Document Type: Article

References (29)

1. C. Hiemke, P. Baumann, N. Bergemann, A. Conca, O. Dietmaier, K. Egberts, M. Fric, M. Gerlach, C. Greiner, G. Gründer, E. Haen, U. Havemann-Reinecke, E. Jaquenoud Sirot, H. Kirchherr, G. Laux, U.C. Lutz, T. Messer, M.J. Müller, B. Pfuhlmann, B. Rambeck, P. Riederer, B. Schoppek, J. Stingl, M. Uhr, S. Ulrich, R. Waschgler, G. Zernig, AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011, Pharmacopsychiatry 44 (2011) 195-235.
2. M. Berna, B. Ackermann, K. Ruterbories, S. Glass, Determination of olanzapine in human blood by liquid chromatography-tandem mass spectrometry, J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 767 (2002) 163-168.
3. M.K. Nielsen, S.S. Johansen, Determination of olanzapine in whole blood using simple protein precipitation and liquid chromatography-tandem mass spectrometry, J. Anal. Toxicol. 33 (2009) 212-217.
4. R.V. Nirogi, V.N. Kandikere, M. Shukla, K. Mudigonda, S. Maurya, R. Boosi, A. Yerramilli, Development and validation of a sensitive liquid chromatography/ electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasma, J. Pharm. Biomed. Anal. 41 (2006) 935-942.
5. D.S. Patel, N. Sharma, M.C. Patel, B.N. Patel, P.S. Shrivastav, M. Sanyal, LC-MS/MS assay for olanzapine in human plasma and its application to a bioequivalence study, Acta Pharm. Sin. B 2 (2012) 481-494.
6. L.J. Dusci, L.P. Hackett, L.M. Fellows, K.F. Ilett, Determination of olanzapine in plasma by high-performance liquid chromatography using ultra-violet absorbance detection, J. Chromatogr. B 773 (2002) 191-197.
7. O.V. Olesen, K. Linnet, Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs, J. Chromatogr. B: Biomed. Sci. Appl. 714 (1998) 309-315.
8. H.A. Lakso, Instability of olanzapine in calf serum, Ther. Drug Monit. 23 (2001) 454-455.
9. J. Sachse, J. Kö ller, S. Härtter, C. Hiemke, Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection, J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 830 (2006) 342-348.
10. R. Karinen, E.L. Øiestad, W. Andresen, A. Smith-Kielland, A. Christophersen, Comparison of the stability of stock solutions of drugs of abuse and other drugs stored in a freezer, refrigerator, and at ambient temperature for up to one year, J. Anal. Toxicol. 35 (2011) 583-590.
11. Z. Zhou, X. Li, K. Li, Z. Xie, Z. Cheng, W. Peng, F. Wang, R. Zhu, H. Li, Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry, J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 802 (2004) 257-262.
12. E. Choong, S. Rudaz, A. Kottelat, D. Guillarme, J.L. Veuthey, C.B. Eap, Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS, J. Pharm. Biomed. Anal. 50 (2009) 1000-1008.
13. K. Titier, S. Bouchet, F. Péhourcq, N. Moore, M. Molimard, High-performance liquid chromatographic method with diode array detection to identify and quantify atypical antipsychotics and haloperidol in plasma after overdose, J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 788 (2003) 179-185.
14. S. Heller, C. Hiemke, G. Stroba, A. Rieger-Gies, E. Daum-Kreysch, J. Sachse, S. Härtter, Assessment of storage and transport stability of new antidepressant and antipsychotic drugs for a nationwide TDM service, Ther. Drug Monit. 26 (2004) 459-461.
15. E. Saar, D. Gerostamoulos, O.H. Drummer, J. Beyer, Assessment of the stability of 30 antipsychotic drugs in stored blood specimens, Forensic Sci. Int. 215 (2011) 152-158.
16. R.J. Flanagan, B. Yusufi, T.R. Barnes, Comparability of whole-blood and plasma clozapine and norclozapine concentrations, Br. J. Clin. Pharmacol. 56 (2003) 135- 138.
17. J. Hermida, E. Paz, J.C. Tutor, Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients, Ther. Drug Monit. 30 (2008) 41-45.
18. D. Remane, M.R. Meyer, D.K. Wissenbach, H.H. Maurer, Ultra high performance liquid chromatographic-tandem mass spectrometric multi-analyte procedure for target screening and quantification in human blood plasma: validation and application for 31 neuroleptics, 28 benzodiazepines, and Z-drugs, Anal. Bioanal. Chem. 401 (2011) 1341-1352.
19. D.S. Fisher, S.J. Partridge, S.A. Handley, L. Couchman, P.E. Morgan, R.J. Flanagan, LC-MS/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood, Forensic Sci. Int., http://dx.doi.org/10.1016/j.forsciint. 2013.02.010, in press
20. E. Saar, J. Beyer, D. Gerostamoulos, O.H. Drummer, The analysis of antipsychotic drugs in human matrices using LC-MS(/MS), Drug Test. Anal. 4 (2012) 376-394.
21. K. Madej, A. Biedron, A. Garbacik, Study of separation and extraction conditions for five neuroleptic drugs by an LLE-HPLC-DAD method in human plasma, J. Liq. Chromatogr. Rel. Technol. 32 (2009) 3025-3037.
22. FDA/CDER Guidance for Industry: Bioanalytical Method Validation, 2001, available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM070107.pdf (accessed 18.0711).
23. W. Li, J. Zhang, F.L. Tse, Strategies in quantitative LC-MS/MS analysis of unstable small molecules in biological matrices, Biomed. Chromatogr. 25 (2011) 258-277.
24. A. Biancotto, X. Feng, M. Langweiler, N.S. Young, J.P. McCoy, Effect of anticoagulants on multiplexed measurement of cytokine/chemokines in healthy subjects, Cytokine 60 (2012) 438-446.
25. C. Chin, Z.P. Zhang, H.T. Karnes, A study of matrix effects on an LC/MS/MS assay for olanzapine and desmethyl olanzapine, J. Pharm. Biomed. Anal. 35 (2004) 1149-1167.
26. A. Kaladjian, B. Bery, E. Deturmeny, B. Bruguerolle, Clozapine monitoring: plasma or serum levels? Ther. Drug Monit. 21 (1999) 327-329.
27. E. Saar, D. Gerostamoulos, O.H. Drummer, J. Beyer, Identification of 2-hydroxymethyl-olanzapine as a novel degradation product of olanzapine, Forensic Sci. Int. 220 (2012) 74-79.
28. K. Kassahun, E. Mattiuz, E. Nyhart Jr., B. Obermeyer, T. Gillespie, A. Murphy, R.M. Goodwin, D. Tupper, J.T. Callaghan, L. Lemberger, Disposition and biotransformation of the antipsychotic agent olanzapine in humans, Drug Metab. Dispos. 25 (1997) 81-93.
29. I.M. McIntyre, T.R. Norman, G.D. Burrows, In vitro stability of nomifensine in plasma, Clin. Chem. 27 (1981) 203-204.